CD8A and hepatocellular carcinoma: PBMCs obtained before and after 6 weeks of therapy with Pembrolizumab in patients with advanced HCC showed that the immune cell distribution was not homogeneous, with levels of CD8 T cells and CD4 T naive cells that differed among the samples, suggesting a role for this imbalance in response modulation [43].